<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02426073</url>
  </required_header>
  <id_info>
    <org_study_id>5312/15</org_study_id>
    <nct_id>NCT02426073</nct_id>
  </id_info>
  <brief_title>Glucose Metabolism, Muscle Mass/Function and Inflammation in the Elderly</brief_title>
  <official_title>Pilot Observational Study to Characterize Glucose Metabolism, Muscle Mass/Function and Inflammatory Profile in Elderly Individuals</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Catholic University of the Sacred Heart</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Rome Tor Vergata</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fondazione Roma</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Catholic University of the Sacred Heart</source>
  <brief_summary>
    <textblock>
      A thorough characterization of glucose metabolism and &quot;inflammaging&quot; in elderly subjects will
      help determine to what extent each of these factors affects muscle mass/function and
      contributes to age-related muscle wasting. The investigators will correlate patterns of
      insulin secretion/sensitivity with &quot;muscle &quot;quality/quantity&quot; in diabetic and non-diabetic
      elderlies (≥70 years old). By comparing different groups (healthy, sarcopenic, diabetic,
      diabetic/sarcopenic), the investigators expect to identify an &quot;oxidative/inflammatory
      signature&quot; (e.g., circulating interleukins/myokines, plasma antioxidant capacity) specific
      for the sarcopenic phenotype and related to muscle insulin resistance.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2017</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Inflammatory markers (TNF-α, interleukin-1, interleukin-2, interleukin-6, RANKL, Myostatin and GDF11)</measure>
    <time_frame>2 years</time_frame>
    <description>The primary objective of the study is to detect differences in inflammatory markers in the four groups</description>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">76</enrollment>
  <condition>Sarcopenia</condition>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>HE</arm_group_label>
    <description>Healthy elderlies</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DM</arm_group_label>
    <description>Elderlies with type 2 diabetes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SA</arm_group_label>
    <description>Elderlies with sarcopenia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DS</arm_group_label>
    <description>Elderlies with both type 2 diabetes and sarcopenia</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Elderly (≥ 70 years) subjects
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetes mellitus: patients taking drugs for diabetes will be diagnosed as
             having diabetes. In all other patients, a diagnosis will be established according to
             the criteria of the American Diabetes Association

          -  Sarcopenia (non-severe): individuals with low muscle mass and either low muscle
             strength or low physical performance will be diagnosed with sarcopenia, according to
             the criteria of the European Working Group on Sarcopenia in Older People (EWGSOP)

          -  Healthy volunteers: no diabetes, no sarcopenia and none of the exclusion criteria

        Exclusion Criteria (overall population):

          -  acute diseases,

          -  chronic obstructive pulmonary disease (COPD)

          -  conditions associated with sarcopenia/altered body composition (e.g. disability,
             altered endocrine function, chronic diseases, nutritional deficiencies, cancer),

          -  obesity (body mass index ≥30 kg/m2)

          -  moderate-severe hepatic disease,

          -  chronic kidney disease (estimated glomerular filtration rate &lt;30 ml/min per 1.73m2),

          -  metal prostheses,

          -  recent or ongoing infection,

          -  inability or unwillingness to provide informed consent

        Exclusion Criteria (diabetic population):

          -  type 1 diabetes,

          -  hemoglobin A1c &gt;8.5% (69 mmol/mol),

          -  basal-bolus insulin therapy,

          -  insulin pump therapy,

          -  proliferative diabetic retinopathy,

          -  diabetic foot.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Catholic University of Sacred Heart</name>
      <address>
        <city>Rome</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Giaccari, MD, PhD</last_name>
      <phone>00390630156664</phone>
      <email>giaccari@rm.unicatt.it</email>
    </contact>
    <investigator>
      <last_name>Andrea Giaccari, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Giovambattista Pani, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale San Giovanni Calibita - Fatebenefratelli Isola Tiberina</name>
      <address>
        <city>Rome</city>
        <zip>00186</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Simona Frontoni, MD</last_name>
      <email>frontoni@uniroma2.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 21, 2015</study_first_submitted>
  <study_first_submitted_qc>April 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 24, 2015</study_first_posted>
  <last_update_submitted>February 8, 2018</last_update_submitted>
  <last_update_submitted_qc>February 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Catholic University of the Sacred Heart</investigator_affiliation>
    <investigator_full_name>Alfredo Pontecorvi</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Inflammaging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Sarcopenia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

